Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Author(s): Ross A. Soo, MBBS, PhD¹; Byoung Chul Cho, MD, PhD²; Joo-Hang Kim, MD³; Myung-Ju Ahn, MD, PhD⁴; Ki Hyeong Lee, MD⁵; Anastasia Zimina, MD⁶; Sergey Orlov, MD⁷; Igor Bondarenko, MD, PhD⁸; Yun-Gyoo Lee, MD⁹; Yueh Ni Lim, MD¹⁰; Sung Sook Lee, MD¹¹; Kyung-Hee Lee, MD, PhD¹²; Yong Kek Pang, MD¹³; Chin Heng Fong, MD¹⁴; Jin Hyoung Kang, MD¹⁵; Chun Sen Lim, MD¹⁶; Pongwut Danchaivijitr, MD¹⁷; Saadettin Kilickap, MD¹⁸; James Chih-Hsin Yang, MD, PhD¹⁹; Cagatay Arslan, MD²⁰; Hana Lee, MS²¹; Seong Nam Park, MPH²¹; Irfan Cicin, MD²²

Source: https://doi.org/10.1016/j.jtho.2023.08.017

Dr. Maen Hussein's Thoughts

Lazertinib, third generation EGFR inhibitor, has good activity in patients with brain mets promising…

INTRODUCTION

Lazertinib, a third-generation mutant-selective EGFR tyrosine kinase inhibitor, improved progression-free survival compared with gefitinib in the phase 3 LASER301 study (ClinicalTrials.gov Identifier: NCT04248829). Here, we report the efficacy of lazertinib and gefitinib in patients with baseline central nervous system (CNS) metastases.

METHODS

Treatment-naive patients with EGFR–mutated advanced NSCLC were randomized one-to-one to lazertinib (240 mg/d) or gefitinib (250 mg/d). Patients with asymptomatic or stable CNS metastases were included if any planned radiation, surgery, or steroids were completed more than 2 weeks before randomization. For patients with CNS metastases confirmed at screening or subsequently suspected, CNS imaging was performed every 6 weeks for 18 months, then every 12 weeks. End points assessed by blinded independent central review and Response Evaluation Criteria in Solid Tumors version 1.1 included intracranial progression-free survival, intracranial objective response rate, and intracranial duration of response.

RESULTS

Of the 393 patients enrolled in LASER301, 86 (lazertinib, n = 45; gefitinib, n = 41) had measurable and or non-measurable baseline CNS metastases. The median intracranial progression-free survival in the lazertinib group was 28.2 months (95% confidence interval [CI]: 14.8–28.2) versus 8.4 months (95% CI: 6.7–not reached [NR]) in the gefitinib group (hazard ratio = 0.42, 95% CI: 0.20–0.89, p = 0.02). Among patients with measurable CNS lesions, the intracranial objective response rate was numerically higher with lazertinib (94%; n = 17) versus gefitinib (73%; n = 11, p = 0.124). The median intracranial duration of response with lazertinib was NR (8.3–NR) versus 6.3 months (2.8–NR) with gefitinib. Tolerability was similar to the overall LASER301 population.

CONCLUSIONS

In patients with CNS metastases, lazertinib significantly improved intracranial progression-free survival compared with gefitinib, with more durable responses.

Author Affiliations

¹Department of Haematology-Oncology, National University Cancer Institute, Singapore; ²Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; ³CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; ⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ⁵Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea; ⁶State Budgetary Healthcare Institution of Omsk Region, Omsk, Russia; ⁷Pavlov State Medical University, Ulitsa L’va Tolstogo, St. Petersburg, Russia; ⁸Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine; ⁹Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ¹⁰Hospital Umum Sarawak, Jalan Hospital, Kuching, Malaysia; ¹¹Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea; ¹²Division of Hematology/Oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea; ¹³University Malaya Medical Centre, University of Malaya, Petaling Jaya, Malaysia; ¹⁴Hospital Pulau Pinang, Pulau Pinang, Malaysia; ¹⁵Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; ¹⁶Oncology Department, Hospital Sultan Ismail, Jalan Mutiara Emas Utama, Johor, Malaysia; ¹⁷Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ¹⁸Department of Medical Oncology, İstinye University Faculty of Medicine, Liv Hospital Ankara, Ankara, Turkey; ¹⁹National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan; ²⁰Department of Medical Oncology, Izmir University of Economics Medical Point Hospital, İzmir, Turkey; ²¹Yuhan Corporation, Seoul, Republic of Korea; ²²Department of Medical Oncology, Trakya University Medical Center, Edirne, Turkey

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

The CHRYSALIS-2, the cohort C analysis of patients with atypical EGFR mutations showed meaningful and durable activity. Atypical mutations can be difficult to deal with as a clinician, and having concrete data on these (S768I, L861Q and G719ZX) mutations gives assurance that this doublet is active. Overall response rate (ORR) was 52% and median progression-free survival (PFS) was 11.1 months in refractory patients and 19.5 months in the treatment-naive population.

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

The final overall survival (OS) analysis from the FLAURA2 confirms the well-published findings that Osi + chemo improves survival over Osi monotherapy. OS difference was about 10 months at 47 vs 37 months, with a predictable toxicity tradeoff.

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer

This update demonstrated that encorafenib plus binimetinib was associated with the longest median overall survival (mOS) reported to date among targeted therapies in patients with treatment-naïve BRAF V600E–mutant metastatic NSCLC (mNSCLC). Median OS was 47.6 months in treatment-naïve patients. By the way check the authors there 😊.

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

PACIFIC-2 was a phase III trial testing durva given concurrently with cCRT (and continued as consolidation) versus placebo + cCRT in unresectable stage III NSCLC, and it did not meet its primary endpoint. The overall response rate (ORR) was essentially identical (60.7% vs 60.6%), and pneumonitis rates were similar (any grade 28.8% vs 28.7%; grade ≥3: 4.6% vs 5.6%), but adverse events (AEs) leading to discontinuation and fatal AEs were higher with durva (25.6% vs 12.0%; 13.7% vs 10.2%), especially early on. Starting IO up front with cCRT didn’t improve outcomes and added early toxicity—consolidation durva after cCRT is still the way to go.

Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer

Sevabertinib shows strong efficacy in HER2-mutant NSCLC, with an overall response rate (ORR) of 64% and median progression-free survival (PFS) of 8.3 months in previously treated, HER2-TKI–naive patients, and an overall response rate (ORR) of 71% with a duration of response (DOR) of 11.0 months in first-line therapy. Activity is highest in TKD mutations, especially Y772_A775dupYVMA, and intracranial responses are seen. Safety is manageable: diarrhea is common but mostly low grade, with grade ≥3 in 5–23% and rare discontinuations. Notably, interstitial lung disease (ILD) was not observed. These data position sevabertinib as a viable oral TKI alongside ADCs for HER2-mutant NSCLC, particularly for TKD/YVMA disease.